drugset / Trial / NCT01889134
OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism
Completed
112 enrolled
Wroclaw Medical University
Ministry of Science and Higher Education, Poland · collab
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this study is to determine whether osteoprotegerin and RANKL (receptor activator of nuclear factor-κB ligand) are involved in bone remodeling in patients with primary hyperparathyroidism (PHPT), and whether alendronate may be useful in treatment of the patients with PHPT who are not treated with parathyroidectomy.
Timeline
- Start
- 2009-01
- Primary completion
- 2012-06
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alendronic Acid | Small molecule | 70 mg | Oral |